CL2017001188A1 - Métodos y formulaciones para tratar enfermedades vasculares de los ojos. - Google Patents

Métodos y formulaciones para tratar enfermedades vasculares de los ojos.

Info

Publication number
CL2017001188A1
CL2017001188A1 CL2017001188A CL2017001188A CL2017001188A1 CL 2017001188 A1 CL2017001188 A1 CL 2017001188A1 CL 2017001188 A CL2017001188 A CL 2017001188A CL 2017001188 A CL2017001188 A CL 2017001188A CL 2017001188 A1 CL2017001188 A1 CL 2017001188A1
Authority
CL
Chile
Prior art keywords
methods
eyes
formulations
vascular diseases
treat vascular
Prior art date
Application number
CL2017001188A
Other languages
English (en)
Spanish (es)
Inventor
Robert L Vitti
Kristine A Erickson
Karen W Chu
Stanley J Wiegand
Jingtai Cao
Ivan B Lobov
Saurabh Wadhwa
Kenneth S Graham
Daniel Dix
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2017001188A1 publication Critical patent/CL2017001188A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
CL2017001188A 2014-11-25 2017-05-10 Métodos y formulaciones para tratar enfermedades vasculares de los ojos. CL2017001188A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084003P 2014-11-25 2014-11-25
US201562147232P 2015-04-14 2015-04-14
US14/943,490 US20160144025A1 (en) 2014-11-25 2015-11-17 Methods and formulations for treating vascular eye diseases

Publications (1)

Publication Number Publication Date
CL2017001188A1 true CL2017001188A1 (es) 2017-11-24

Family

ID=56009149

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001188A CL2017001188A1 (es) 2014-11-25 2017-05-10 Métodos y formulaciones para tratar enfermedades vasculares de los ojos.

Country Status (18)

Country Link
US (3) US20160144025A1 (OSRAM)
EP (1) EP3224278A4 (OSRAM)
JP (2) JP2017536414A (OSRAM)
KR (1) KR20170087950A (OSRAM)
CN (1) CN107001457A (OSRAM)
AU (1) AU2015353838A1 (OSRAM)
BR (1) BR112017009807A2 (OSRAM)
CA (1) CA2968522A1 (OSRAM)
CL (1) CL2017001188A1 (OSRAM)
CO (1) CO2017004715A2 (OSRAM)
EA (1) EA201791168A1 (OSRAM)
IL (1) IL252159B (OSRAM)
MA (2) MA41028A (OSRAM)
MX (1) MX2017006129A (OSRAM)
PE (1) PE20170900A1 (OSRAM)
PH (1) PH12017500834A1 (OSRAM)
SG (1) SG11201703609UA (OSRAM)
WO (1) WO2016085750A1 (OSRAM)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102614134B (zh) 2005-03-25 2016-09-07 瑞泽恩制药公司 Vegf拮抗剂制剂
ES2643469T3 (es) 2006-04-07 2017-11-23 Aerpio Therapeutics, Inc. Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y usos de los mismos
RU2432155C3 (ru) 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
MY160399A (en) 2009-07-06 2017-03-15 Aerpio Therapeutics Inc Compounds, compositions, and methods for preventing metastasis of cancer cells
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
WO2014127479A1 (en) 2013-02-21 2014-08-28 Rsem, Limited Partnership Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
US11104730B2 (en) 2013-11-20 2021-08-31 Regeneren Pharmaceuticals, Inc. Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JP6726734B2 (ja) * 2015-03-26 2020-07-22 アイコー，エルエルシー 画像解析のためのシステム
MY194736A (en) 2015-09-23 2022-12-15 Aerpio Therapeutics Inc Methods of treating intraocular pressure with activators of tie-2
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CA3030298A1 (en) 2016-07-20 2018-01-25 Aerpio Therapeutics, Inc. Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.)
US20200056186A1 (en) 2016-09-22 2020-02-20 Rsem, Limited Partnership Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence
JPWO2018070390A1 (ja) * 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
EA201992630A1 (ru) * 2017-05-06 2020-04-29 Ридженерон Фармасьютикалз, Инк. Способы лечения заболеваний глаз антагонистами aplnr и ингибиторами vegf
TWI774827B (zh) * 2017-08-18 2022-08-21 美商雷傑納榮製藥公司 使用影像毛細管等電聚焦以分析樣品基質中蛋白質變異體之方法
SMT202200374T1 (it) * 2017-11-30 2022-11-18 Regeneron Pharma Uso di un antagonista del vegf per trattare disturbi angiogenici dell’occhio
WO2019124946A1 (ko) * 2017-12-22 2019-06-27 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
ES3009668T3 (en) 2018-01-26 2025-03-31 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
JP7005772B2 (ja) * 2018-02-06 2022-02-10 エフ．ホフマン－ラ ロシュ アーゲー 眼科疾患の処置
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
CN108671229B (zh) * 2018-05-08 2022-03-25 华博生物医药技术（上海）有限公司 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂
KR20210021299A (ko) 2018-05-10 2021-02-25 리제너론 파아마슈티컬스, 인크. 고농도 vegf 수용체 융합 단백질 함유 제제
US11518819B2 (en) * 2018-08-17 2022-12-06 Trican Biotechnology Co., Ltd Anti-angiogenesis fusion protein and uses thereof
CN109598628B (zh) * 2018-11-30 2022-09-20 平安医疗健康管理股份有限公司 医保欺诈行为的识别方法、装置、设备及可读存储介质
JOP20210152A1 (ar) 2018-12-18 2023-01-30 Novartis Ag صياغة محلول بروتيني محتوية على تركيز عالٍ من جسم مضاد لـ vegf
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
US11253502B2 (en) 2019-04-29 2022-02-22 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the Schlemm's canal
CN110423281B (zh) * 2019-07-31 2021-04-30 成都金唯科生物科技有限公司 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
EP4065150A4 (en) 2019-11-25 2023-12-06 The Regents of the University of California LONG-ACTING VEGF INHIBITORS FOR INTRAVASCULAR NEOVASCULARIZATION
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
JP2023523246A (ja) * 2020-04-29 2023-06-02 ノバルティス アーゲー 患者の眼における疾患又は症状の活動性レベルを評価するためのコンピュータ実施システム及び方法
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
CA3190173A1 (en) * 2020-06-22 2021-12-30 Innovent Biologics (Suzhou) Co., Ltd. Anti-ang-2 antibody and use thereof
KR102690020B1 (ko) * 2020-07-24 2024-08-01 (주)팬젠 안과용 액상 조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
WO2005072772A1 (en) * 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
RU2432155C3 (ru) * 2006-06-16 2017-11-17 Ридженерон Фармасьютикалз, Инк. Составы антагониста vegf, подходящие для интравитреального введения
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
CA2665956A1 (en) * 2009-05-07 2010-11-07 Samir Patel Combination treatment for ocular diseases
WO2010136492A2 (en) 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
US20120189635A1 (en) * 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
MX385629B (es) 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
NZ627859A (en) * 2012-01-23 2015-09-25 Regeneron Pharma Stabilized formulations containing anti-ang2 antibodies
MX361337B (es) * 2012-07-13 2018-12-04 Roche Glycart Ag Anticuerpos biespecificos anti-factor de crecimiento endotelial vascular humano (vegf) / anti-angiopoyetina-2 humana (ang-2) y su uso en el tratamiento de enfermedades vasculares oculares.
EP3851454A1 (en) * 2012-12-05 2021-07-21 Novartis AG Compositions and methods for antibodies targeting epo
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
KR20160030504A (ko) * 2013-07-11 2016-03-18 노파르티스 아게 미숙아 망막병증의 치료에 있어서 vegf 길항제의 용도
US9914769B2 (en) * 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele

Also Published As

Publication number Publication date
KR20170087950A (ko) 2017-07-31
US20170080086A1 (en) 2017-03-23
SG11201703609UA (en) 2017-06-29
EP3224278A4 (en) 2018-07-11
EA201791168A1 (ru) 2017-09-29
JP2017536414A (ja) 2017-12-07
MA41028A (fr) 2017-10-03
US20160144025A1 (en) 2016-05-26
MA40306A1 (fr) 2019-03-29
PH12017500834A1 (en) 2017-10-30
PE20170900A1 (es) 2017-07-12
AU2015353838A1 (en) 2017-06-08
US20190117767A1 (en) 2019-04-25
CA2968522A1 (en) 2016-06-02
MX2017006129A (es) 2018-04-10
IL252159B (en) 2021-03-25
CN107001457A (zh) 2017-08-01
JP2021046431A (ja) 2021-03-25
EP3224278A1 (en) 2017-10-04
WO2016085750A1 (en) 2016-06-02
IL252159A0 (en) 2017-07-31
US11071780B2 (en) 2021-07-27
BR112017009807A2 (pt) 2018-02-27
CO2017004715A2 (es) 2017-09-20

Similar Documents

Publication Publication Date Title
CL2017001188A1 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos.
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
CY1121348T1 (el) Mrna θεραπεια για την θεραπευτικη αγωγη οφθαλμικων ασθενειων
AR103130A1 (es) Sonda de vitrectomía con un escáner de fibra óptica
PH12016502167A1 (en) Hdl theraphy markers
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
MX2015011131A (es) Composiciones, formulaciones y metodos para tratar enfermedades oculares.
MX2019005402A (es) Terapias de combinacion del inhibidor de arginasa.
GT201700167A (es) Terapias de combinación para el tratamiento de cánceres.
CL2015002485A1 (es) Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares
MX2017016518A (es) Composiciones y metodos para la mejora de la vision a distancia y el tratamiento de errores de refraccion del ojo.
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
PE20151925A1 (es) Anticuerpos anti-igf-1r con abolicion de la union al fcrn y su utilizacion en el tratamiento de enfermedades oculares vasculares
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
ZA202503387B (en) Semaglutide in medical therapy
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
MX392383B (es) Metodos para tratar afecciones oculares.
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2016016928A (es) Composiciones parasiticidas que comprenden derivados de indol, metodos y usos de los mismos.
EA201691773A1 (ru) Галогенированные хиназолин-thf-амины в качестве ингибиторов pde1
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential